Santos-Silva AR, Witjes MJH, Shaw RJ, Kanatas A, Vissink A, Treister NS. Iatrogenic Head and Neck Necrosis of Bone and Soft Tissue in Cancer Patients.
Oral Dis 2025. [PMID:
40411292 DOI:
10.1111/odi.15378]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2024] [Revised: 04/15/2025] [Accepted: 04/27/2025] [Indexed: 05/26/2025]
Abstract
BACKGROUND
Cancer patients are at risk of developing a wide range of treatment-related toxicities that may affect the head and neck region. Iatrogenic necrosis of bone and soft tissue in this area represents a distinct clinical entity characterized by significant complexities and challenges, arising as a consequence of radiotherapy (osteoradionecrosis) or the administration of bone-modifying and/or antiangiogenic therapies (medication-related osteonecrosis of the jaw).
OBJECTIVE
This review provides a comprehensive understanding of this potentially highly impactful complication of cancer therapy and antiresorptive therapy by examining its pathophysiology, risk factors, clinical presentation, and management strategies.
RESULTS
Risk factors associated with these conditions include radiotherapy-related variables, medication-related factors, and local predisposing conditions.
CONCLUSION
This review highlights the importance of preventive strategies, including comprehensive dental evaluations and the development of personalized treatment plans before, during, and after cancer therapy, as well as when patients are undergoing or are expected to undergo treatment with bone-modifying medications. By addressing these critical aspects, clinicians can better manage and mitigate the impact of this challenging complication on the quality of life and morbidity outcomes.
Collapse